Lion Biotechnologies Inc. (LBIO) Trading Down 4.9%
Lion Biotechnologies Inc. (NASDAQ:LBIO)’s share price was down 4.9% on Tuesday . The company traded as low as $8.55 and last traded at $8.59, with a volume of 118,854 shares. The stock had previously closed at $9.03.
A number of equities analysts have recently weighed in on LBIO shares. FBR & Co reiterated a “buy” rating on shares of Lion Biotechnologies in a report on Monday, June 6th. Zacks Investment Research raised Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $8.50 target price on the stock in a research note on Tuesday, June 14th. SunTrust Banks Inc. lowered Lion Biotechnologies from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $37.00 to $30.50 in a research note on Monday, June 6th. Roth Capital reissued a “buy” rating and set a $15.00 target price on shares of Lion Biotechnologies in a research note on Saturday, July 9th. Finally, Chardan Capital reissued a “buy” rating on shares of Lion Biotechnologies in a research note on Saturday, June 4th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $19.17.
The stock’s 50 day moving average price is $8.26 and its 200-day moving average price is $6.29. The company’s market cap is $439.88 million.
Lion Biotechnologies (NASDAQ:LBIO) last posted its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.02. On average, equities research analysts expect that Lion Biotechnologies Inc. will post ($0.73) earnings per share for the current fiscal year.
Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.